Tumor-associated carbohydrate antigens: A possible avenue for cancer prevention

Yanfei Xu, Alessandro Sette, John Sidney, Sandra J Gendler, Alessandra Franco

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Here we examine the use of glycopeptides containing tumour-associated carbohydrate antigens (TACA) as potential preventive vaccines for carcinomas. Our recent results suggest that CD8+ T cells (CTL) are capable of recognizing TACA in a conventional class I MHC-restricted fashion. The Thomsen-Friedenreich antigen (TF), a disaccharide, and Tn, its immediate precursor, are TACA largely expressed in carcinomas. TF and Tn can be successfully used as Th-independent vaccines when conjugated to designer peptides with optimal binding affinity for class I MHC molecules. TF- and Tn-specific CTL generated using this strategy are capable of recognizing TACA-expressing tumours in vitro, suggesting that glycopeptides are as effectively presented by class I MHC molecules as non-glycosylated peptides. Because the exact sequences of endogenously synthesized glycopeptides are unknown, the TACA-specific T cell repertoire elicited by carbohydrate-based vaccines is assumed to be degenerate. Here we report that mice genetically manipulated to develop TACA-expressing mammary tumours are not tolerant to glycopeptide vaccination. Moreover, we tested the immunogenicity of designer glycopeptides capable of binding multiple HLA alleles as a novel approach for the development of vaccines potentially useful for vaccination of a large fraction of the general population. Our results have suggested that CTL derived from normal donors respond with high efficiency to glycopeptides in vitro, opening a new avenue for the design of prospective vaccines for cancer prevention.

Original languageEnglish (US)
Pages (from-to)440-448
Number of pages9
JournalImmunology and Cell Biology
Volume83
Issue number4
DOIs
StatePublished - Aug 2005

Fingerprint

Tumor-Associated Carbohydrate Antigens
Glycopeptides
T-cells
Vaccines
T-Lymphocytes
Neoplasms
Tumors
Vaccination
Carcinoma
Peptides
Cancer Vaccines
Molecules
Disaccharides
Alleles
Carbohydrates
Breast Neoplasms
Population

Keywords

  • Glycopeptide
  • Immunotherapy
  • TACA
  • Tn

ASJC Scopus subject areas

  • Immunology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Tumor-associated carbohydrate antigens : A possible avenue for cancer prevention. / Xu, Yanfei; Sette, Alessandro; Sidney, John; Gendler, Sandra J; Franco, Alessandra.

In: Immunology and Cell Biology, Vol. 83, No. 4, 08.2005, p. 440-448.

Research output: Contribution to journalArticle

Xu, Yanfei ; Sette, Alessandro ; Sidney, John ; Gendler, Sandra J ; Franco, Alessandra. / Tumor-associated carbohydrate antigens : A possible avenue for cancer prevention. In: Immunology and Cell Biology. 2005 ; Vol. 83, No. 4. pp. 440-448.
@article{53e23556289545419a7f25175cf5940c,
title = "Tumor-associated carbohydrate antigens: A possible avenue for cancer prevention",
abstract = "Here we examine the use of glycopeptides containing tumour-associated carbohydrate antigens (TACA) as potential preventive vaccines for carcinomas. Our recent results suggest that CD8+ T cells (CTL) are capable of recognizing TACA in a conventional class I MHC-restricted fashion. The Thomsen-Friedenreich antigen (TF), a disaccharide, and Tn, its immediate precursor, are TACA largely expressed in carcinomas. TF and Tn can be successfully used as Th-independent vaccines when conjugated to designer peptides with optimal binding affinity for class I MHC molecules. TF- and Tn-specific CTL generated using this strategy are capable of recognizing TACA-expressing tumours in vitro, suggesting that glycopeptides are as effectively presented by class I MHC molecules as non-glycosylated peptides. Because the exact sequences of endogenously synthesized glycopeptides are unknown, the TACA-specific T cell repertoire elicited by carbohydrate-based vaccines is assumed to be degenerate. Here we report that mice genetically manipulated to develop TACA-expressing mammary tumours are not tolerant to glycopeptide vaccination. Moreover, we tested the immunogenicity of designer glycopeptides capable of binding multiple HLA alleles as a novel approach for the development of vaccines potentially useful for vaccination of a large fraction of the general population. Our results have suggested that CTL derived from normal donors respond with high efficiency to glycopeptides in vitro, opening a new avenue for the design of prospective vaccines for cancer prevention.",
keywords = "Glycopeptide, Immunotherapy, TACA, Tn",
author = "Yanfei Xu and Alessandro Sette and John Sidney and Gendler, {Sandra J} and Alessandra Franco",
year = "2005",
month = "8",
doi = "10.1111/j.1440-1711.2005.01347.x",
language = "English (US)",
volume = "83",
pages = "440--448",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Tumor-associated carbohydrate antigens

T2 - A possible avenue for cancer prevention

AU - Xu, Yanfei

AU - Sette, Alessandro

AU - Sidney, John

AU - Gendler, Sandra J

AU - Franco, Alessandra

PY - 2005/8

Y1 - 2005/8

N2 - Here we examine the use of glycopeptides containing tumour-associated carbohydrate antigens (TACA) as potential preventive vaccines for carcinomas. Our recent results suggest that CD8+ T cells (CTL) are capable of recognizing TACA in a conventional class I MHC-restricted fashion. The Thomsen-Friedenreich antigen (TF), a disaccharide, and Tn, its immediate precursor, are TACA largely expressed in carcinomas. TF and Tn can be successfully used as Th-independent vaccines when conjugated to designer peptides with optimal binding affinity for class I MHC molecules. TF- and Tn-specific CTL generated using this strategy are capable of recognizing TACA-expressing tumours in vitro, suggesting that glycopeptides are as effectively presented by class I MHC molecules as non-glycosylated peptides. Because the exact sequences of endogenously synthesized glycopeptides are unknown, the TACA-specific T cell repertoire elicited by carbohydrate-based vaccines is assumed to be degenerate. Here we report that mice genetically manipulated to develop TACA-expressing mammary tumours are not tolerant to glycopeptide vaccination. Moreover, we tested the immunogenicity of designer glycopeptides capable of binding multiple HLA alleles as a novel approach for the development of vaccines potentially useful for vaccination of a large fraction of the general population. Our results have suggested that CTL derived from normal donors respond with high efficiency to glycopeptides in vitro, opening a new avenue for the design of prospective vaccines for cancer prevention.

AB - Here we examine the use of glycopeptides containing tumour-associated carbohydrate antigens (TACA) as potential preventive vaccines for carcinomas. Our recent results suggest that CD8+ T cells (CTL) are capable of recognizing TACA in a conventional class I MHC-restricted fashion. The Thomsen-Friedenreich antigen (TF), a disaccharide, and Tn, its immediate precursor, are TACA largely expressed in carcinomas. TF and Tn can be successfully used as Th-independent vaccines when conjugated to designer peptides with optimal binding affinity for class I MHC molecules. TF- and Tn-specific CTL generated using this strategy are capable of recognizing TACA-expressing tumours in vitro, suggesting that glycopeptides are as effectively presented by class I MHC molecules as non-glycosylated peptides. Because the exact sequences of endogenously synthesized glycopeptides are unknown, the TACA-specific T cell repertoire elicited by carbohydrate-based vaccines is assumed to be degenerate. Here we report that mice genetically manipulated to develop TACA-expressing mammary tumours are not tolerant to glycopeptide vaccination. Moreover, we tested the immunogenicity of designer glycopeptides capable of binding multiple HLA alleles as a novel approach for the development of vaccines potentially useful for vaccination of a large fraction of the general population. Our results have suggested that CTL derived from normal donors respond with high efficiency to glycopeptides in vitro, opening a new avenue for the design of prospective vaccines for cancer prevention.

KW - Glycopeptide

KW - Immunotherapy

KW - TACA

KW - Tn

UR - http://www.scopus.com/inward/record.url?scp=22944440380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944440380&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1711.2005.01347.x

DO - 10.1111/j.1440-1711.2005.01347.x

M3 - Article

C2 - 16033540

AN - SCOPUS:22944440380

VL - 83

SP - 440

EP - 448

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 4

ER -